ELVN — Enliven Therapeutics Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
- Latest Close
- $44.25
- 30-Day Move
- +157.7%
- Market Cap
- $2.3B
- Shares Outstanding
- 59,800,000
- P/B Ratio
- 1.99
- ROE
- -22.6%
Enliven Therapeutics Inc
A read-only Alphactor snapshot forEnliven Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$44.25
30-Day Move
+157.7%
Market Cap
$2.3B
Shares Outstanding
59,800,000
P/B Ratio
1.99
ROE
-22.6%
$44.25
+157.7%last 90 delayed daily bars
90D High
$48.53
90D Low
$14.79
Avg Volume
1,201,427
ELVN is up 157.7% over the last 30 trading days shown on this page.
Latest operating income is $-120M, which helps anchor the headline ratios with an actual earnings figure.
Latest Close
$44.25
30-Day Move
+157.7%
Market Cap
$2.3B
Shares Outstanding
59,800,000
P/B Ratio
1.99
ROE
-22.6%
ROA
-21.8%
Debt / Equity
0
Current Ratio
28.66
Latest Revenue
$0
Revenue
$0
Gross Profit
--
Operating Income
$-120M
Net Income
$-104M
Gross Margin
--
Net Margin
--
Current Ratio
28.66
Debt / Equity
0.00
Altman Z
83.40
Safe
Piotroski
3
Weak (0-3)
Cash Conversion
0.68x
Rule of 40
--
Insufficient data
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-39M | $-38M | $-33M |
| 2023-12-31 | $0 | $-84M | $-72M | $-61M |
| 2024-12-31 | $0 | $-105M | $-89M | $-73M |
| 2025-12-31 | $0 | $-120M | $-104M | $-70M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
FMR LLC (Fidelity)
Filed 2026-02-17
$109M
-0.3%
BlackRock
Filed 2024-08-13
$64M
--
Vanguard Group
Filed 2025-11-07
$52M
+5.9%
Citadel Advisors
Filed 2025-08-14
$29M
--
Capital Research Global Investors
Filed 2025-11-13
$27M
--
Geode Capital Management
Filed 2025-11-12
$22M
+22.9%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.